Patanjali Ayurved burst onto the Indian consumer scene as a symbol of swadeshi pride and Ayurvedic revival, disrupting multinational giants with affordable herbal products. Backed by yoga guru Baba Ramdev’s massive popularity, the brand experienced meteoric growth in its early years. However, rapid expansion brought regulatory battles, quality controversies, and a slowdown that many labeled as its “fall.” Today, the Patanjali group is showing signs of stabilization and diversification. Here’s a detailed look at its journey and what the future may hold.

The Spectacular Rise (2006–Mid-2010s)

Founded in 2006 in Haridwar by Baba Ramdev and Acharya Balkrishna, Patanjali Ayurved started with a focus on traditional Ayurvedic medicines and personal care items. Ramdev’s widely watched yoga programs on television provided powerful, low-cost marketing, building deep consumer trust among those seeking natural alternatives to chemical-laden products.

The brand perfectly timed its entry into the market amid rising health awareness, nationalism, and demand for “Made in India” goods. It offered high-quality herbal products at competitive prices, quickly capturing significant market share in categories like toothpaste, ghee, oils, biscuits, and juices. By around 2016–2017, Patanjali had reportedly achieved a turnover of ₹5,000–10,000 crore, challenging established players such as Hindustan Unilever and Colgate. Its success story became a textbook example of how strong branding, cultural resonance, and aggressive distribution could fuel explosive growth in India’s FMCG sector.

Challenges and the So-Called “Fall” (Late 2010s–Early 2020s)

The rapid ascent was followed by hurdles that slowed momentum. Revenue and profit growth stagnated in some years, with reports of dips around 2017–18. Several factors contributed to this correction:

• Controversial Advertising Claims: Patanjali faced repeated criticism and legal action over advertisements promising cures for serious conditions like diabetes, cancer, and even COVID-19. The Supreme Court and various regulators, including the Indian Medical Association, took notice, leading to ad bans, product license suspensions, and public scrutiny.
• Quality and Regulatory Issues: Some products failed quality tests, prompting actions from state governments and the Food Safety and Standards Authority of India (FSSAI). These incidents damaged the brand’s carefully built reputation for purity.
• Operational Strain: Over-expansion into dozens of product categories created supply chain and distribution challenges. Reports also highlighted alleged fund-related issues (which the company denied) and tax concerns.

During this phase, Patanjali shifted focus from pure Ayurveda toward broader FMCG offerings. While this helped sustain presence, it also diluted its original herbal identity in the eyes of some consumers and analysts.

Current Standing of the Patanjali Group (2025–2026)

Patanjali operates through interconnected entities, with clearer separation between its Ayurvedic medicines and food businesses in recent years.

• Patanjali Ayurved Ltd continues to focus on medicines, personal care, and wellness. It reported revenue of around ₹5,860 crore in FY25 and has pursued diversification, including an insurance venture and new projects like hospitals.
• Patanjali Foods Ltd (the listed entity, formerly Ruchi Soya) has emerged as the stronger performer. It dominates in edible oils while expanding into value-added FMCG and home & personal care (HPC) products. Recent quarterly results showed healthy revenue growth, with full-year figures crossing significant milestones and improved profitability.

The group has undertaken internal restructuring, such as the transfer of non-food businesses, to unlock synergies. Legal cases have seen some relief, and the company is investing in new areas like renewables, hospitality, and e-commerce.

What Does the Future Hold?

Patanjali’s future appears cautiously optimistic. The brand retains strong cultural equity, especially in Tier 2 and Tier 3 cities and among Ayurveda enthusiasts. Key positive drivers include:

• Continued momentum in the foods business with ambitious revenue and EBITDA targets.
• Diversification beyond core FMCG into insurance, wellness infrastructure, and digital channels.
• Alignment with national trends favoring wellness, indigenous products, and self-reliance.

However, significant challenges remain:

• Ongoing regulatory scrutiny and the need for stricter compliance on claims and quality.
• Intense competition from both multinational corporations and nimble D2C herbal brands.
• Dependence on the founders’ image and the ability to professionalize management for sustainable scaling.

Analysts believe long-term success will depend on balancing Ayurvedic roots with modern FMCG discipline, investing in innovation, and rebuilding trust through transparent practices.

Key Business Lessons from Patanjali’s Journey

Patanjali demonstrates the immense power of storytelling, trust, and affordability in building a consumer brand in India. At the same time, it highlights the risks of unsubstantiated claims, unstructured growth, and underestimating regulatory frameworks. For other Indian startups and heritage brands, the story underscores the importance of professional governance and consistent quality as the company matures.

As of mid-2026, Patanjali is not in decline but in a phase of consolidation and strategic evolution. Whether it can reclaim its peak growth trajectory will depend on execution in a highly competitive and tightly regulated market. Consumers and investors alike will be watching closely to see if the Ayurvedic pioneer can turn past lessons into future strengths.

For the latest updates, refer to the company’s official filings and earnings reports.

About The Author